Funato Tadao, Takeda Mayu
Division of Healthcare Economics and Quality Management, Tohoku Fukushi University, Sendai 981-8522, Japan.
Rinsho Byori. 2010 Feb;58(2):169-74.
Targeted therapy refers to anticancer treatment which specifically targets key molecules of cancer cells. The higher levels of expression of the epidermal growth factor receptor (EGFR) have also been shown to be correlated with non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC). Potential biomarkers should be investigated for the selection of patients with NSCLC most likely to benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib. Cetuximab is a monoclonal antibody that binds with high affinity to the EGFR, which is a prime target for new anticancer therapy. However, the predictive value of EGFR expression and mutation of the K-ras gene has been assessed in response to cetuximab. Many molecular techniques are available to assay for these biomarkers. In this review, we present the current assessments of evidence for using these methods as biomarkers for molecular target-based therapy.
靶向治疗是指专门针对癌细胞关键分子的抗癌治疗。表皮生长因子受体（EGFR）的较高表达水平也已被证明与非小细胞肺癌（NSCLC）和结直肠癌（CRC）相关。应研究潜在的生物标志物，以选择最有可能从表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）（如吉非替尼）中获益的非小细胞肺癌患者。西妥昔单抗是一种与EGFR高亲和力结合的单克隆抗体，EGFR是新抗癌疗法的主要靶点。然而，EGFR表达和K-ras基因突变的预测价值已在西妥昔单抗的疗效评估中得到评估。有许多分子技术可用于检测这些生物标志物。在本综述中，我们介绍了目前对将这些方法用作基于分子靶点治疗的生物标志物的证据评估。
